MEDINDIA
English
हिन्दी
Español
français
中文
Email
4-Phenylbutyric Acid
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Budesonide.
Aceclofenac
The risk or severity of adverse effects can be increased when Aceclofenac is combined with Budesonide.
Acemetacin
The risk or severity of adverse effects can be increased when Acemetacin is combined with Budesonide.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Budesonide.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Budesonide.
Aldesleukin
Budesonide may decrease the antineoplastic activities of Aldesleukin.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Budesonide.
Aloxiprin
The risk or severity of adverse effects can be increased when Aloxiprin is combined with Budesonide.
Aluminum
The bioavailability of Budesonide can be decreased when combined with Aluminium.
Aluminum Hydroxide
The bioavailability of Budesonide can be decreased when combined with Aluminum hydroxide.
aluminum hydroxide, dried (USP)
The bioavailability of Budesonide can be decreased when combined with Aluminum hydroxide.
Aluminum Magnesium Silicate
The bioavailability of Budesonide can be decreased when combined with Almasilate.
Ambenonium
The risk or severity of adverse effects can be increased when Budesonide is combined with Ambenonium.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Budesonide.
Amiodarone
The serum concentration of Budesonide can be increased when it is combined with Amiodarone.
Amoxapine
The therapeutic efficacy of Budesonide can be decreased when used in combination with Amoxapine.
Amphotericin B
Budesonide may increase the hypokalemic activities of Amphotericin B.
amphotericin B liposomal
Budesonide may increase the hypokalemic activities of Amphotericin B.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Budesonide.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Budesonide is combined with Anthrax immune globulin human.
Antipyrine
The risk or severity of adverse effects can be increased when Antipyrine is combined with Budesonide.
Apalutamide
The serum concentration of Budesonide can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Budesonide.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Budesonide.
Aprepitant
The serum concentration of Budesonide can be increased when it is combined with Aprepitant.
Aspirin
The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Budesonide.
Atazanavir
The serum concentration of Budesonide can be increased when it is combined with Atazanavir.
Atomoxetine
The serum concentration of Budesonide can be increased when it is combined with Atomoxetine.
Atracurium Besylate
Atracurium besylate may increase the adverse neuromuscular activities of Budesonide.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Budesonide.
Azosemide
Budesonide may increase the hypokalemic activities of Azosemide.
Balsalazide
The risk or severity of adverse effects can be increased when Balsalazide is combined with Budesonide.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Budesonide.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Budesonide is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Budesonide is combined with Bacillus calmette-guerin substrain tice live antigen.
Bendroflumethiazide
Budesonide may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic Acid
The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Budesonide.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Budesonide.
Bismuth Subcitrate
The bioavailability of Budesonide can be decreased when combined with Bismuth Subcitrate.
Boceprevir
The serum concentration of Budesonide can be increased when it is combined with Boceprevir.
Bortezomib
The serum concentration of Budesonide can be increased when it is combined with Bortezomib.
Bosentan
The serum concentration of Budesonide can be decreased when it is combined with Bosentan.
Brigatinib
The serum concentration of Budesonide can be decreased when it is combined with Brigatinib.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Bufexamac is combined with Budesonide.
Bumetanide
Budesonide may increase the hypokalemic activities of Bumetanide.
Calcitriol
The therapeutic efficacy of Calcitriol can be decreased when used in combination with Budesonide.
Calcium Carbonate
The bioavailability of Budesonide can be decreased when combined with Calcium Carbonate.
CALCIUM CARBONATE, PRECIPITATED
The bioavailability of Budesonide can be decreased when combined with Calcium Carbonate.
Capromab Pendetide
Budesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.
Carbamazepine
The metabolism of Budesonide can be increased when combined with Carbamazepine.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Budesonide.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Budesonide.
Ceritinib
The serum concentration of Budesonide can be increased when it is combined with Ceritinib.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Budesonide.
Chlorothiazide
Budesonide may increase the hypokalemic activities of Chlorothiazide.
Chlorotrianisene
The serum concentration of Budesonide can be increased when it is combined with Chlorotrianisene.
Chlorthalidone
Budesonide may increase the hypokalemic activities of Chlorthalidone.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Budesonide.
Cinoxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Cinoxacin.
Clarithromycin
The serum concentration of Budesonide can be increased when it is combined with Clarithromycin.
Clemastine
The serum concentration of Budesonide can be increased when it is combined with Clemastine.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Budesonide.
Clotrimazole
The serum concentration of Budesonide can be increased when it is combined with Clotrimazole.
Cobicistat
The serum concentration of Budesonide can be increased when it is combined with Cobicistat.
Colesevelam
Colesevelam can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Budesonide.
Corticorelin Ovine
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Budesonide.
Corticorelin Ovine Triflutate
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Budesonide.
Crizotinib
The serum concentration of Budesonide can be increased when it is combined with Crizotinib.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Budesonide.
Cyclopenthiazide
Budesonide may increase the hypokalemic activities of Cyclopenthiazide.
Cyclosporine
The serum concentration of Budesonide can be increased when it is combined with Cyclosporine.
Dabrafenib
The serum concentration of Budesonide can be decreased when it is combined with Dabrafenib.
Danazol
Budesonide may increase the fluid retaining activities of Danazol.
Darunavir
The serum concentration of Budesonide can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Budesonide can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Budesonide can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Budesonide can be decreased when it is combined with Deferasirox.
Delavirdine
The serum concentration of Budesonide can be increased when it is combined with Delavirdine.
Demecarium
The risk or severity of adverse effects can be increased when Budesonide is combined with Demecarium.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Budesonide.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Budesonide.
Dienestrol
The serum concentration of Budesonide can be increased when it is combined with Dienestrol.
Diethylstilbestrol
The serum concentration of Budesonide can be increased when it is combined with Diethylstilbestrol.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Budesonide.
Dihydroergotamine
The serum concentration of Budesonide can be increased when it is combined with Dihydroergotamine.
Diltiazem
The serum concentration of Budesonide can be increased when it is combined with Diltiazem.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Budesonide.
Distigmine
The risk or severity of adverse effects can be increased when Budesonide is combined with Distigmine.
Donepezil
The risk or severity of adverse effects can be increased when Budesonide is combined with Donepezil.
Doxycycline
The serum concentration of Budesonide can be increased when it is combined with Doxycycline.
Doxycycline Anhydrous
The serum concentration of Budesonide can be increased when it is combined with Doxycycline.
Dronedarone
The serum concentration of Budesonide can be increased when it is combined with Dronedarone.
Droxicam
The risk or severity of adverse effects can be increased when Droxicam is combined with Budesonide.
Echothiophate
The risk or severity of adverse effects can be increased when Budesonide is combined with Echothiophate.
Edrophonium
The risk or severity of adverse effects can be increased when Budesonide is combined with Edrophonium.
Enoxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Enoxacin.
Enzalutamide
The serum concentration of Budesonide can be decreased when it is combined with Enzalutamide.
Equol, (-)-
The serum concentration of Budesonide can be increased when it is combined with Equol.
Erythromycin
The serum concentration of Budesonide can be increased when it is combined with Erythromycin.
Estradiol
The serum concentration of Budesonide can be increased when it is combined with Estradiol.
Estradiol acetate
The serum concentration of Budesonide can be increased when it is combined with Estradiol acetate.
Estradiol Cypionate
The serum concentration of Budesonide can be increased when it is combined with Estradiol cypionate.
Estradiol Valerate
The serum concentration of Budesonide can be increased when it is combined with Estradiol valerate.
Estriol
The serum concentration of Budesonide can be increased when it is combined with Estriol.
Estrogens, Conjugated (USP)
The serum concentration of Budesonide can be increased when it is combined with Conjugated estrogens.
Estrogens, Esterified (USP)
The serum concentration of Budesonide can be increased when it is combined with Estrogens, esterified.
Estrone
The serum concentration of Budesonide can be increased when it is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Budesonide.
Ethacrynate
Budesonide may increase the hypokalemic activities of Etacrynic acid.
Ethacrynic Acid
Budesonide may increase the hypokalemic activities of Etacrynic acid.
Ethinyl Estradiol
The serum concentration of Budesonide can be increased when it is combined with Ethinyl Estradiol.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Budesonide.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Budesonide.
Etoricoxib
The risk or severity of adverse effects can be increased when Etoricoxib is combined with Budesonide.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Budesonide.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Budesonide.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Budesonide.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Budesonide.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Budesonide.
Fingolimod
Budesonide may increase the immunosuppressive activities of Fingolimod.
Fleroxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Budesonide.
Fluconazole
The serum concentration of Budesonide can be increased when it is combined with Fluconazole.
Flumequine
The risk or severity of adverse effects can be increased when Budesonide is combined with Flumequine.
Fluoxymesterone
Budesonide may increase the fluid retaining activities of Fluoxymesterone.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Budesonide.
Fluvoxamine
The serum concentration of Budesonide can be increased when it is combined with Fluvoxamine.
Fosamprenavir
The serum concentration of Budesonide can be increased when it is combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Budesonide can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The metabolism of Budesonide can be increased when combined with Fosphenytoin.
Furosemide
Budesonide may increase the hypokalemic activities of Furosemide.
Fusidate
The serum concentration of Budesonide can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Budesonide can be increased when it is combined with Fusidic Acid.
Galantamine
The risk or severity of adverse effects can be increased when Budesonide is combined with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Budesonide is combined with Gallamine Triethiodide.
Gatifloxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin.
Gatifloxacin Anhydrous
The risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin.
Gemifloxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Gemifloxacin.
Gemifloxacin Mesylate
The risk or severity of adverse effects can be increased when Budesonide is combined with Gemifloxacin.
Genistein
The serum concentration of Budesonide can be increased when it is combined with Genistein.
Ginkgo biloba extract
The risk or severity of adverse effects can be increased when Budesonide is combined with Ginkgo biloba.
Glycerol Phenylbutyrate
The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Budesonide.
Grepafloxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Grepafloxacin.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Budesonide is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Budesonide is combined with Hepatitis B Vaccine (Recombinant).
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Budesonide.
Hyaluronidase, Ovine
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Budesonide.
Hydrochlorothiazide
Budesonide may increase the hypokalemic activities of Hydrochlorothiazide.
Hydroflumethiazide
Budesonide may increase the hypokalemic activities of Hydroflumethiazide.
Hydrotalcite
The bioavailability of Budesonide can be decreased when combined with Hydrotalcite.
Hypoxis hemerocallidea root extract
The serum concentration of Budesonide can be decreased when it is combined with St. John's Wort.
Ibuprofen
The risk or severity of adverse effects can be increased when Ibuprofen is combined with Budesonide.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Budesonide.
Idelalisib
The serum concentration of Budesonide can be increased when it is combined with Idelalisib.
Imatinib
The serum concentration of Budesonide can be increased when it is combined with Imatinib.
Indacaterol
Indacaterol may increase the hypokalemic activities of Budesonide.
Indapamide
Budesonide may increase the hypokalemic activities of Indapamide.
Indinavir
The serum concentration of Budesonide can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Budesonide can be increased when it is combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Budesonide.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Budesonide.
Isavuconazole
The serum concentration of Budesonide can be increased when it is combined with Isavuconazole.
Isavuconazonium
The serum concentration of Budesonide can be increased when it is combined with Isavuconazonium.
Isoflurophate
The risk or severity of adverse effects can be increased when Budesonide is combined with Isoflurophate.
Isoniazid
The serum concentration of Isoniazid can be decreased when it is combined with Budesonide.
Isradipine
The serum concentration of Budesonide can be increased when it is combined with Isradipine.
Itraconazole
The serum concentration of Budesonide can be increased when it is combined with Itraconazole.
Ivacaftor
The serum concentration of Budesonide can be increased when it is combined with Ivacaftor.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Budesonide.
Ketoconazole
The serum concentration of Budesonide can be increased when it is combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Ketoprofen is combined with Budesonide.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Budesonide.
Lacidipine
The serum concentration of Lacidipine can be decreased when it is combined with Budesonide.
Leflunomide
The risk or severity of adverse effects can be increased when Budesonide is combined with Leflunomide.
Levofloxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin.
Levofloxacin Anhydrous
The risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Budesonide.
Lopinavir
The serum concentration of Budesonide can be increased when it is combined with Lopinavir.
Lornoxicam
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Budesonide.
Lovastatin
The serum concentration of Budesonide can be increased when it is combined with Lovastatin.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Budesonide.
Luliconazole
The serum concentration of Budesonide can be increased when it is combined with Luliconazole.
Lumacaftor
The metabolism of Budesonide can be increased when combined with Lumacaftor.
Magaldrate
The bioavailability of Budesonide can be decreased when combined with Magaldrate.
Magnesium Hydroxide
The bioavailability of Budesonide can be decreased when combined with Magnesium hydroxide.
Magnesium Oxide
The bioavailability of Budesonide can be decreased when combined with Magnesium oxide.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Budesonide.
Magnesium Trisilicate
The bioavailability of Budesonide can be decreased when combined with Magnesium Trisilicate.
Malathion
The risk or severity of adverse effects can be increased when Budesonide is combined with Malathion.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Budesonide.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Budesonide.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Budesonide.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Budesonide.
Mefloquine
The risk or severity of adverse effects can be increased when Budesonide is combined with Mefloquine.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Budesonide.
Memantine
The risk or severity of adverse effects can be increased when Budesonide is combined with Memantine.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Budesonide.
Mesterolone
Budesonide may increase the fluid retaining activities of Mesterolone.
Mestranol
The serum concentration of Budesonide can be increased when it is combined with Mestranol.
Methyclothiazide
Budesonide may increase the hypokalemic activities of Methyclothiazide.
Methyl Salicylate
The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Budesonide.
Methyltestosterone
Budesonide may increase the fluid retaining activities of Methyltestosterone.
Metoclopramide
The risk or severity of adverse effects can be increased when Budesonide is combined with Metoclopramide.
Metolazone
Budesonide may increase the hypokalemic activities of Metolazone.
Mifepristone
The therapeutic efficacy of Budesonide can be decreased when used in combination with Mifepristone.
Minaprine
The risk or severity of adverse effects can be increased when Budesonide is combined with Minaprine.
Mitotane
The serum concentration of Budesonide can be decreased when it is combined with Mitotane.
Mivacurium
Mivacurium may increase the adverse neuromuscular activities of Budesonide.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Budesonide.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Budesonide.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Budesonide.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Budesonide.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Budesonide.
Nalidixic Acid
The risk or severity of adverse effects can be increased when Budesonide is combined with Nalidixic Acid.
Nandrolone
Budesonide may increase the fluid retaining activities of Nandrolone.
Nandrolone Decanoate
Budesonide may increase the fluid retaining activities of Nandrolone decanoate.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Budesonide.
Natalizumab
The risk or severity of adverse effects can be increased when Budesonide is combined with Natalizumab.
Nefazodone
The serum concentration of Budesonide can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Budesonide can be increased when it is combined with Nelfinavir.
Neostigmine
The risk or severity of adverse effects can be increased when Budesonide is combined with Neostigmine.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Budesonide.
Netupitant
The serum concentration of Budesonide can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of Budesonide can be increased when it is combined with Nevirapine.
Nicorandil
The risk or severity of adverse effects can be increased when Budesonide is combined with Nicorandil.
Niflumic Acid
The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Budesonide.
Nilotinib
The serum concentration of Budesonide can be increased when it is combined with Nilotinib.
Nimesulide
The risk or severity of adverse effects can be increased when Nimesulide is combined with Budesonide.
Norfloxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Norfloxacin.
O-PHENANTHROLINE
The risk or severity of adverse effects can be increased when Budesonide is combined with 1,10-Phenanthroline.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Budesonide.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Budesonide.
Olaparib
The serum concentration of Budesonide can be increased when it is combined with Olaparib.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Budesonide.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Budesonide.
Osimertinib
The serum concentration of Budesonide can be increased when it is combined with Osimertinib.
Oxandrolone
Budesonide may increase the fluid retaining activities of Oxandrolone.
Oxaprozin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Budesonide.
Oxymetholone
Budesonide may increase the fluid retaining activities of Oxymetholone.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Budesonide.
Palbociclib
The serum concentration of Budesonide can be increased when it is combined with Palbociclib.
Parecoxib
The risk or severity of adverse effects can be increased when Parecoxib is combined with Budesonide.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Budesonide.
Pefloxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Pefloxacin.
Pentobarbital
The metabolism of Budesonide can be increased when combined with Pentobarbital.
Phenobarbital
The metabolism of Budesonide can be increased when combined with Phenobarbital.
Phenylacetic Acid
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Budesonide.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Budesonide.
Phenylbutyrate
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Budesonide.
Phenytoin
The metabolism of Budesonide can be increased when combined with Phenytoin.
Physostigmine
The risk or severity of adverse effects can be increased when Budesonide is combined with Physostigmine.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Budesonide.
Piretanide
Budesonide may increase the hypokalemic activities of Piretanide.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Budesonide.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Budesonide.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Budesonide.
Polyestradiol Phosphate
The serum concentration of Budesonide can be increased when it is combined with Polyestradiol phosphate.
Polythiazide
Budesonide may increase the hypokalemic activities of Polythiazide.
Posaconazole
The serum concentration of Budesonide can be increased when it is combined with Posaconazole.
Primidone
The metabolism of Budesonide can be increased when combined with Primidone.
Promestriene
The serum concentration of Budesonide can be increased when it is combined with Promestriene.
Pyridostigmine
The risk or severity of adverse effects can be increased when Budesonide is combined with Pyridostigmine.
Pyridostigmine Bromide
The risk or severity of adverse effects can be increased when Budesonide is combined with Pyridostigmine.
Quinestrol
The serum concentration of Budesonide can be increased when it is combined with Quinestrol.
Quinethazone
Budesonide may increase the hypokalemic activities of Quinethazone.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Budesonide is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Budesonide.
Ranolazine
The serum concentration of Budesonide can be increased when it is combined with Ranolazine.
Rapacuronium
Rapacuronium may increase the adverse neuromuscular activities of Budesonide.
Resveratrol
The risk or severity of adverse effects can be increased when Resveratrol is combined with Budesonide.
Ribociclib
The serum concentration of Budesonide can be increased when it is combined with Ribociclib.
Rifabutin
The metabolism of Budesonide can be increased when combined with Rifabutin.
Rifampin
The metabolism of Budesonide can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Budesonide can be increased when combined with Rifapentine.
Rivastigmine
The risk or severity of adverse effects can be increased when Budesonide is combined with Rivastigmine.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Budesonide.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Budesonide.
Rosoxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Budesonide is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Budesonide is combined with Rubella virus vaccine.
Rucaparib
The serum concentration of Budesonide can be increased when it is combined with Rucaparib.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Budesonide.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Budesonide.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Budesonide is combined with Salmonella typhi ty21a live antigen.
Salsalate
The risk or severity of adverse effects can be increased when Salsalate is combined with Budesonide.
Saquinavir
The serum concentration of Budesonide can be increased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Budesonide can be increased when it is combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Budesonide can be decreased when used in combination with Sarilumab.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Budesonide.
Sildenafil
The serum concentration of Budesonide can be increased when it is combined with Sildenafil.
Siltuximab
The serum concentration of Budesonide can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Budesonide can be increased when it is combined with Simeprevir.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Budesonide.
Sodium Bicarbonate
The bioavailability of Budesonide can be decreased when combined with Sodium bicarbonate.
Sparfloxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Sparfloxacin.
ST. JOHN'S WORT EXTRACT
The serum concentration of Budesonide can be decreased when it is combined with St. John's Wort.
Stanozolol
Budesonide may increase the fluid retaining activities of Stanozolol.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Budesonide.
Sulfisoxazole
The serum concentration of Budesonide can be increased when it is combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Budesonide.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Budesonide.
synthetic conjugated estrogens, A
The serum concentration of Budesonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
The serum concentration of Budesonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.
Tacrine
The risk or severity of adverse effects can be increased when Budesonide is combined with Tacrine.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Budesonide.
Telaprevir
The serum concentration of Budesonide can be increased when it is combined with Telaprevir.
Telithromycin
The serum concentration of Budesonide can be increased when it is combined with Telithromycin.
Temafloxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Temafloxacin.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Budesonide.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Budesonide.
Testosterone
Budesonide may increase the fluid retaining activities of Testosterone.
Testosterone Cypionate
Budesonide may increase the fluid retaining activities of Testosterone cypionate.
Testosterone Enanthate
Budesonide may increase the fluid retaining activities of Testosterone enanthate.
Testosterone Propionate
Budesonide may increase the fluid retaining activities of Testosterone propionate.
Testosterone Undecanoate
Budesonide may increase the fluid retaining activities of Testosterone undecanoate.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Budesonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Budesonide.
Tibolone
The serum concentration of Budesonide can be increased when it is combined with Tibolone.
Ticlopidine
The serum concentration of Budesonide can be increased when it is combined with Ticlopidine.
Tocilizumab
The serum concentration of Budesonide can be decreased when it is combined with Tocilizumab.
Tofacitinib
Budesonide may increase the immunosuppressive activities of Tofacitinib.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Budesonide.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Budesonide.
Torsemide
Budesonide may increase the hypokalemic activities of Torasemide.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Budesonide.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Budesonide.
Trichlormethiazide
Budesonide may increase the hypokalemic activities of Trichlormethiazide.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Budesonide.
Tromethamine
The bioavailability of Budesonide can be decreased when combined with Tromethamine.
Trovafloxacin
The risk or severity of adverse effects can be increased when Budesonide is combined with Trovafloxacin.
Tubocurarine
The risk or severity of adverse effects can be increased when Budesonide is combined with Tubocurarine.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Budesonide is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Budesonide is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Budesonide.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Budesonide is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vemurafenib
The serum concentration of Budesonide can be decreased when it is combined with Vemurafenib.
Venlafaxine
The serum concentration of Budesonide can be increased when it is combined with Venlafaxine.
Verapamil
The serum concentration of Budesonide can be increased when it is combined with Verapamil.
Voriconazole
The serum concentration of Budesonide can be increased when it is combined with Voriconazole.
Warfarin
Budesonide may increase the anticoagulant activities of Warfarin.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Budesonide is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Budesonide is combined with Yellow Fever Vaccine.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Budesonide.
Ziprasidone
The serum concentration of Budesonide can be increased when it is combined with Ziprasidone.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Budesonide.
